Compare · CYCN vs JNJ
CYCN vs JNJ
Side-by-side comparison of Cyclerion Therapeutics Inc. (CYCN) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYCN and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $651.20B, about 41400.5x CYCN ($15.7M).
- Over the past year, CYCN is up 35.7% and JNJ is up 55.1% - JNJ leads by 19.4 points.
- CYCN has been more active in the news (17 items in the past 4 weeks vs 13 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 2 for CYCN).
- Company
- Cyclerion Therapeutics Inc.
- Johnson & Johnson
- Price
- $3.37-21.93%
- $270.25+1.11%
- Market cap
- $15.7M
- $651.20B
- 1M return
- -8.29%
- -0.26%
- 1Y return
- +35.71%
- +55.14%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 17
- 13
- Recent ratings
- 2
- 25
Cyclerion Therapeutics Inc.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest CYCN
- SEC Form SCHEDULE 13D filed by Cyclerion Therapeutics Inc.
- Cyclerion Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Regulation FD Disclosure
- SEC Form 4 filed by Director Pernice Michelle Patricia
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- SEC Form 4 filed by Director Shah Nimish P
- SEC Form 4 filed by Director Gottesdiener Andrew
- New insider Violin Jonathan claimed ownership of 207,400 shares (SEC Form 3)
- SEC Form 3 filed by new insider Leoni Matthew James
- SEC Form 3 filed by new insider Pernice Michelle Patricia
- SEC Form 3 filed by new insider Henson Heidi
Latest JNJ
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
- Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
- SEC Form 4 filed by Director Pinto Daniel E
- SEC Form 4 filed by Director Woods Eugene A.
- SEC Form 4 filed by Director Hewson Marillyn A
- Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
- Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
- EVP, WW Chair, MedTech Schmid Timothy exercised 33,597 shares at a strike of $144.99 and sold $9,230,440 worth of shares (33,597 units at $274.74) (SEC Form 4)
- Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
- UBS resumed coverage on Johnson & Johnson with a new price target